Revenio operates within ophthalmological devices and software solutions for eye care. The company develops tonometers (intraocular pressure measurement device), fundus imaging devices, perimeters and clinical software solutions under the iCare brand focusing on early-stage detection of globally prevailing eye diseases, including glaucoma, diabetic retinopathy, age-related macular degeneration (AMD) and cataract as well as the monitoring of these diseases during the treatment process.
Revenio is headquartered in Helsinki, Finland, and has almost 200 employees. In 2022, the company’s net sales totaled EUR 97 million with an adjusted EBITDA margin of 34%. Revenio Group is listed on Nasdaq OMX Helsinki.
William Demant Invest started investing in Revenio in 2018 and is today the largest shareholder with approx. 18% ownership.